GENERIC DRUG COMPANY EXECS TO MEET WITH FDA TOPSIDERS ON OCT. 21
GENERIC DRUG COMPANY EXECS TO MEET WITH FDA TOPSIDERS ON OCT. 21 as part of the agency's effort to provide executives from the regulated industry with a better understanding of drug approval process at the working level. The generic drug industry meeting will be between about two dozen representatives of GPIA (Generic Pharmaceutical Industry Association) companies and 20 FDAers. It is one of a series of meetings that FDA Commissioner Young is urging the agency managers to have with their counterparts in the private sector. In February, FDA held a similar meeting with CEOs from the brandname drug industry. No formal agenda has been set for the Oct. 21 meeting. From FDA's perspective, the function of the meeting is to provide company heads an opportunity to meet agency topsiders and to learn about FDA's regulatory review process. For example, directors from some of the divisions under New Drug Evaluation are expected to attend the meeting. Those divisions, which usually handle full NDAs, are sometimes consulted during the course of ANDA review. FDA officials expected to attend the meeting include: Deputy Commissioner John Norris; Office of Drug Research and Review Director Robert Temple, MD; Office of Drug Standards Director Peter Rheinstein, MD, and/or Deputy Director James Morrison; and Generic Drug Division Director Marvin Seife, MD. FDA management from the Division of Bioequivalence, the Office of Compliance, and the Office of Epidemiology and Biostatistics are also scheduled to attend. GPIA members scheduled to attend the meeting include the heads of Barr, Biocraft, Bolar, Chelsea, Danbury, Geneva Generics, Lemmon, Mylan, Par and Zenith.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth